MOBILion Systems Unveils Novel Ion Mobility Product at ASMS 2020
Product News Jun 02, 2020
MOBILion Systems, Inc. is showcasing its first ion mobility separations product to the biopharma drug development and academic research markets, with data from its first beta users, during the American Society for Mass Spectrometry’s (ASMS) virtual conference.
MOBILion Systems is commercializing its patented ion mobility separations technology, called Structures for Lossless Ion Manipulation (SLIMTM), to efficiently separate, identify and analyze the most challenging, clinically significant molecules that other instruments fail to detect. MOBILion’s product can be integrated with LC-MS workflows to provide more robust analytical information, and for some applications, replace liquid chromatography to provide superior resolution, speed, ease of use and greater instrument uptime. MOBILion has partnered with Agilent Technologies Inc. to integrate SLIM with Agilent’s Q-TOF mass spectrometry platform as the company’s first commercial product offering, to be fully commercialized in 2021. MOBILion’s novel technology combined with Agilent’s high-performance Q-TOF platform aims to provide enhanced throughput, resolution, and ease of use, eliminating the drawbacks of existing LC-MS workflows, while enabling multi-dimensional analysis of biologically relevant molecules.
SLIM provides rapid, high resolution separations in the gas phase on printed circuit boards, effectively digitizing separations prior to MS analysis. With a 13-meter serpentine ion path length in a component that is 14 x 18 inches, the new product breaks the boundaries of linear path for unparalleled resolution and throughput.
Melissa Sherman, CEO at MOBILion Systems, said: “We are excited to be sharing more information about our first product with the market during ASMS week. Working with key beta users, we have been able to demonstrate that we can separate and identify the most challenging clinically significant molecules that incumbent LC-MS instruments either fail to detect, or would take hours of analysis time vs. minutes with SLIM. We also provide additional deeper level structural information, which is critically important for our pharmaceutical customers to more completely understand the function of biologic therapeutics. This is all possible with easier push-button software-driven methods, greater instrument uptime, reduced operator skill and cost, and 10x to 100x faster analysis.”